Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abrocitinib

FDA-approved product (tablet, oral), marketed as Cibinqo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abrocitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abrocitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abrocitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

    NCT03742336 · start 2018-11-21

    Registered record
    Registry ID
    NCT03742336
    Conditions
    Healthy
    Interventions
    PF-04965842; Dabigatran
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-11-21
    Completion
    2019-02-18
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; Dabigatran
    PhasePhase 1
    Registry statusCompleted

  • A Renal Impairment Study for PF-04965842

    NCT03660241 · start 2018-10-05

    Registered record
    Registry ID
    NCT03660241
    Conditions
    Renal Impairment
    Interventions
    PF-04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-05
    Completion
    2019-11-05
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionPF-04965842
    PhasePhase 1
    Registry statusCompleted

  • A Hepatic Impairment Study for PF-04965842.

    NCT03626415 · start 2018-10-01

    Registered record
    Registry ID
    NCT03626415
    Conditions
    Hepatic Impairment
    Interventions
    PF-04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2019-04-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionPF-04965842
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

    NCT03662516 · start 2018-09-26

    Registered record
    Registry ID
    NCT03662516
    Conditions
    Healthy Females
    Interventions
    PF-04965842; Ethinyl estradiol (EE) and levonorgestrel (LN)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-26
    Completion
    2019-01-19
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Females
    InterventionPF-04965842; Ethinyl estradiol (EE) and levonorgestrel (LN)
    PhasePhase 1
    Registry statusCompleted

  • Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.

    NCT03637790 · start 2018-09-13

    Registered record
    Registry ID
    NCT03637790
    Conditions
    Healthy
    Interventions
    PF-04965842; rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-13
    Completion
    2018-12-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; rifampin
    PhasePhase 1
    Registry statusCompleted

  • Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

    NCT03634345 · start 2018-09-12

    Registered record
    Registry ID
    NCT03634345
    Conditions
    Dermatitis, Atopic
    Interventions
    Period 1 - Day 1: PF-04965842 administered; Period 2: Cohort 1: Fluvoxamine & PF-04965842; Period 2: Cohort 2: Fluconazole & PF-04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-12
    Completion
    2018-12-13
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionPeriod 1 - Day 1: PF-04965842 administered; Period 2: Cohort 1: Fluvoxamine & PF-04965842; Period 2: Cohort 2: Fluconazole & PF-04965842
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

    NCT03647670 · start 2018-07-03

    Registered record
    Registry ID
    NCT03647670
    Conditions
    Phase 1
    Interventions
    PF-04965842; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-03
    Completion
    2018-10-16
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhase 1
    InterventionPF-04965842; Midazolam
    PhasePhase 1
    Registry statusCompleted

  • A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

    NCT03386279 · start 2018-07-02

    Registered record
    Registry ID
    NCT03386279
    Conditions
    Healthy Volunteers
    Interventions
    PF-04965842; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-02
    Completion
    2018-10-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPF-04965842; Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

    NCT03575871 · start 2018-06-29

    Registered record
    Registry ID
    NCT03575871
    Conditions
    Dermatitis, Atopic
    Interventions
    PF-04965842 100 mg; PF-04965842 200 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-29
    Completion
    2019-08-13
    Enrolment
    391

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionPF-04965842 100 mg; PF-04965842 200 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

    NCT03627767 · start 2018-06-11

    Registered record
    Registry ID
    NCT03627767
    Conditions
    Dermatitis; Dermatitis, Atopic; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases
    Interventions
    PF-04965842 100 mg; PF-04965842 200 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-11
    Completion
    2020-10-07
    Enrolment
    1,235

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis; Dermatitis, Atopic; Eczema; Skin Diseases +6 more
    InterventionPF-04965842 100 mg; PF-04965842 200 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis

    NCT03549416 · start 2018-01-01

    Registered record
    Registry ID
    NCT03549416
    Conditions
    Atopic Dermatitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-01-01
    Completion
    2028-12-31
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

    NCT03349060 · start 2017-12-07

    Registered record
    Registry ID
    NCT03349060
    Conditions
    Dermatitis, Atopic
    Interventions
    PF-04965842 100 mg; PF-04965842 200 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-07
    Completion
    2019-03-26
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionPF-04965842 100 mg; PF-04965842 200 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Absorption, Metabolism, Excretion and Absolute Bioavailability

    NCT03250039 · start 2017-07-10

    Registered record
    Registry ID
    NCT03250039
    Conditions
    Healthy
    Interventions
    PF-04965842; Absolute Bioavailability
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-07-10
    Completion
    2017-09-15
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; Absolute Bioavailability
    PhasePhase 1
    Registry statusCompleted

  • Molecular Signatures in Inflammatory Skin Disease

    NCT03358693 · start 2017-01-20

    Registered record
    Registry ID
    NCT03358693
    Conditions
    Atopic Dermatitis; Psoriasis
    Interventions
    Anti-TNF; Anti-IL12/23; Anti-IL17; Dupilumab; Anti-IL23; Baricitinib; Abrocitinib; Upadacitinib; Tralokinumab; Lebrikizumab; Nemolizumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2017-01-20
    Completion
    2029-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Psoriasis
    InterventionAnti-TNF; Anti-IL12/23; Anti-IL17; Dupilumab +7 more
    PhaseNot recorded
    Registry statusRecruiting

  • Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

    NCT02780167 · start 2016-04

    Registered record
    Registry ID
    NCT02780167
    Conditions
    Atopic Dermatitis
    Interventions
    PF-04965842; PF-04965842; PF-04965842; PF-04965842; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-04
    Completion
    2017-04
    Enrolment
    269

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPF-04965842; PF-04965842; PF-04965842; PF-04965842 +1 more
    PhasePhase 2
    Registry statusCompleted